Encouraging data from 2nd dose cohort in CLTX CAR T trial
Filed with ASX · · 3 pages · English
• Encouraging safety for dual routes (intratumoral and intraventricular) of CLTX chimeric antigen receptor (CAR) T cell administration as therapy was generally well tolerated • Initial signal for activity was demonstrated with 2/3 evaluable patients achieving local stability of disease rd • The 3 dose cohort of the phase 1 clinical trial is now open to enrollment with dual 6 ASX leader in cell the
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Sponsored Research Agreement with University of Pennsylvania
- Chimeric receives US patent covering CLTX CAR technology
- Transformative Portfolio Expansion Presentation
- CLTX CAR T data shows regional control of tumour recurrence
- CLTX CAR t presents positive initial phase 1 clinical data
Later from Chimeric Therapeutics
- Entitlement Offer to raise approximately $18.1 million
- Successful completion of Institutional Entitlement Offer
- Chimeric partners with Be the Match BioTherapies
- Final Results in Phase 1 Trial of CORE NK Platform
- Security Class Suspension from Quotation CHMO
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics